Overview

Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib

Status:
Active, not recruiting

Trial end date:
2021-10-28

Target enrollment:

Participant gender:

Summary

To assess longitudinal changes in allele frequency of ESR1 mutation in plasma in patients treated with Fulvestrant plus palbociclib compared to tamoxifen plus palbociclib

Phase:

Early Phase 1

Details

Lead Sponsor:

Shannon Puhalla
University of Pittsburgh

Treatments:

Estradiol
Fulvestrant
Palbociclib
Tamoxifen